>Since Merrimack needs AFP and just raised 60 mil, anyone think they will go for CD137 not only for its intrinsic value but also as a way to insure gtcb's health re afp?<
Unlikely, IMO. The $60M is to develop the drug candidates that Merrimack already has, not to in-license new ones.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”